Progress in immunoconjugate cancer therapeutics

Cancer Cell

Volumn 3, Issue 3, 2003, Pages 207-212

  Payne, Gillian ^a  

^a IMMUNOGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIBODY CONJUGATE; ANTIINFECTIVE AGENT; ASTATINE 211; AURISTATIN PE; BB 10901; BISMUTH 212; BISMUTH 213; BISMUTH DERIVATIVE; CALICHEAMICIN; CANTUZUMAB MERTANSINE; CD20 ANTIGEN; DOCETAXEL; DOXORUBICIN; DUOCARMYCIN DERIVATIVE; EPITOPE; ESPERAMICIN; ETOPOSIDE; FOLIC ACID ANTAGONIST; IBRITUMOMAB TIUXETAN; IODINE 131; PACLITAXEL; RACHELMYCIN; TAXOID; TENASCIN; TOSITUMOMAB I 131; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID; YTTRIUM 90; CANCER ANTIBODY; CYTOTOXIN; IMMUNOTOXIN; MONOCLONAL ANTIBODY;

ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; BREAST CANCER; CANCER; CANCER THERAPY; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONCENTRATION RESPONSE; DISEASE COURSE; ESOPHAGUS CARCINOMA; GENOMICS; HAIRY CELL LEUKEMIA; HUMAN; IMMUNOTHERAPY; LUNG CARCINOMA; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN ANALYSIS; PROTEOMICS; REVIEW; STOMACH CANCER; ANIMAL; IMMUNOLOGY; METABOLISM; NEOPLASM; RADIOIMMUNOTHERAPY; SCINTISCANNING;

VINCA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CYTOTOXINS; EPITOPES; HUMANS; IMMUNOCONJUGATES; IMMUNOTOXINS; NEOPLASMS; RADIOIMMUNOTHERAPY;

EID: 0042787657     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00057-6     Document Type: Review

References (42)

1. Ajani J.A., Kelsen D.P., Haller D., Hargraves K., Healey D. Cancer J. 6:2000;78-81.
2. Andersson H., Palm S., Lindegren S., Back T., Jacobsson L., Leser G., Horvath G. Anticancer Res. 21:2001;409-412.
3. Ballangrud A.M., Yang W.H., Charlton D.E., McDevitt M.R., Hamacher K.A., Panageas K.S., Ma D., Bander N.H., Scheinberg D.A., Sgouros G. Cancer Res. 61:2001;2008-2014.
4. Blättler W.A., Chari R.V.J. Drugs to Enhance the Therapeutic Potency of Anticancer Antibodies: Antibody-Drug Conjugates as Tumor-Activated Prodrugs. Ojima I., Vite G.D., Altmann K.-H. Anticancer Agents-Frontiers in Cancer Chemotherapy. 2001;317-338 American Chemical Society, Washington, DC.
5. Blättler W.A., Chari R.V.J., Lambert J.M. Immunoconjugates. Teicher B. Cancer Therapeutics: Experimental and Clinical Agents. 1996;371-394 Humana Press Inc. Totowa, NJ.
6. Bross P.F., Beitz J., Chen G., Chen X.H., Duffy E., Kieffer L., Roy S., Sridhara R., Rahman A., Williams G., Pazdur R. Clin. Cancer Res. 7:2001;1490-1496.
7. Chari R.V. Adv. Drug Deliv. Rev. 31:1998;89-104.
8. Chari R.V., Jackel K.A., Bourret L.A., Derr S.M., Tadayoni B.M., Mattocks K.M., Shah S.A., Liu C., Blättler W.A., Goldmacher V.S. Cancer Res. 55:1995;4079-4084.
9. Cheson B.D. Blood. 101:2003;391-398.
10. Fosella, F.V., Tolcher, A., Elliott, M., Lambert, J.M., Lu, R., Zinner, R., Lu, C., Oh, Y., Forouzesh, B., McCreary, H., et al. (2002). Phase I trial of the monoclonal antibody conjugate, BB-10901, for relapsed/refractory small cell lung cancer (SCLC) and other neuroendrocrine (NE) tumors. Abstract #1232, American Society of Clinical Oncology (Orlando, FL: American Society for Clinical Oncology), 309a.
11. Helft, P.R., Schilsky, R.L., Kindler, H.L., Bertucci, D., Dewitte, M.H., Martino, H.K., Friedman, C.J., Erickson, J.C., Lambert, J.M., Ratain, M.J. (2001). A phase I study of SB-408075 administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Abstract #657 AACR-NCI-EORTC International Conference (Miami Beach, FL: American Association for Cancer Res), 134.
12. Jurcic J.G., Larson S.M., Sgouros G., McDevitt M.R., Finn R.D., Divgi C.R., Ballangrud A.M., Hamacher K.A., Ma D., Humm J.L., et al. Blood. 100:2002;1233-1239.
13. Kingston D.G., Chaudhary A.G., Chordia M.D., Gharpure M., Gunatilaka A.A., Higgs P.I., Rimoldi J.M., Samala L., Jagtap P.G., Giannakakou P., et al. J. Med. Chem. 41:1998;3715-3726.
14. Krebs B., Rauchenberger R., Reiffert S., Rothe C., Tesar M., Thomassen E., Cao M., Dreier T., Fischer D., Hoss A., et al. J. Immunol. Methods. 254:2001;67-84.
15. Kreitman R.J. Curr. Pharm. Biotechnol. 2:2001;313-325.
16. Kreitman R.J., Wilson W.H., White J.D., Stetler-Stevenson M., Jaffe E.S., Giardina S., Waldmann T.A., Pastan I. J. Clin. Oncol. 18:2000;1622-1636.
17. Kreitman R.J., Wilson W.H., Bergeron K., Raggio M., Stetler-Stevenson M., FitzGerald D.J., Pastan I. N. Engl. J. Med. 345:2001;241-247.
18. Kuan C.T., Pai L.H., Pastan I. Clin. Cancer Res. 1:1995;1589-1594.
19. Larsen R.H., Akabani G., Welsh P., Zalutsky M.R. Radiat. Res. 149:1998;155-162.
20. Liu C., Tadayoni B.M., Bourret L.A., Mattocks K.M., Derr S.M., Widdison W.C., Kedersha N.L., Ariniello P.D., Goldmacher V.S., Lambert J.M., et al. Proc. Natl. Acad. Sci. USA. 93:1996;8618-8623.
21. Lutz, R.J., Xie, H., Dionne, C., Steeves, R.M., Goldmacher, V.S., Leece, B., Bartle, L., Chari, R. (2002). Eradication of acute myeloid leukemia xenografts by an anti-CD33-DM1 immunoconjugate. Abstract #1279, American Association for Cancer Res.(San Francisco, CA: American Association for Cancer Res.), 257.
22. McDevitt M.R., Barendswaard E., Ma D., Lai L., Curcio M.J., Sgouros G., Ballangrud A.M., Yang W.H., Finn R.D., Pellegrini V., et al. Cancer Res. 60:2000;6095-6100.
23. McDevitt M.R., Ma D., Lai L.T., Simon J., Borchardt P., Frank R.K., Wu K., Pellegrini V., Curcio M.J., Miederer M., et al. Science. 294:2001;1537-1540.
24. McDevitt M.R., Scheinberg D.A. Cell Death Differ. 9:2002;593-594.
25. Ojima I., Geng X., Wu X., Qu C., Borella C.P., Xie H., Wilhelm S.D., Leece B.A., Bartle L.M., Goldmacher V.S., Chari R.V. J. Med. Chem. 45:2002;5620-5623.
26. Olsen E., Duvic M., Frankel A., Kim Y., Martin A., Vonderheid E., Jegasothy B., Wood G., Gordon M., Heald P., et al. J. Clin. Oncol. 19:2001;376-388.
27. Pegram M.D., Lipton A., Hayes D.F., Weber B.L., Baselga J.M., Tripathy D., Baly D., Baughman S.A., Twaddell T., Glaspy J.A., Slamon D.J. J. Clin. Oncol. 16:1998;2659-2671.
28. Posey J.A., Khazaeli M.B., Bookman M.A., Nowrouzi A., Grizzle W.E., Thornton J., Carey D.E., Lorenz J.M., Sing A.P., Siegall C.B., et al. Clin. Cancer Res. 8:2002;3092-3099.
29. Reardon D.A., Akabani G., Coleman R.E., Friedman A.H., Friedman H.S., Herndon J.E. 2nd, Cokgor I., McLendon R.E., Pegram C.N., Provenzale J.M., et al. J. Clin. Oncol. 20:2002;1389-1397.
30. Reff M.E., Heard C. Crit. Rev. Oncol. Hematol. 40:2001;25-35.
31. Ross S., Spencer S.D., Holcomb I., Tan C., Hongo J., Devaux B., Rangell L., Keller G.A., Schow P., Steeves R.M., et al. Cancer Res. 62:2002;2546-2553.
32. Rowinsky, E.K., Ochoa, L., Patnaik, A., de Bono, J.S., Hammond, L.A., Takimoto, C., Garrison, M.A., Schwartz, G., Smith, L., Hao, D., et al. (2002). SB-408075, a tumor-activated immunoconjugate targeting the C242 Can Ag antigen with a potent maytansinoid payload: phaseI, pharmacokinetic (PK), and biological studies. Abstract #118, American Society of Clinical Oncology (Orlando, FL: American Society of Clinical Oncology), 30a.
33. Saleh M.N., Sugarman S., Murray J., Ostroff J.B., Healey D., Jones D., Daniel C.R., LeBherz D., Brewer H., Onetto N., LoBuglio A.F. J. Clin. Oncol. 18:2000;2282-2292.
34. Schwall, R.H., Dugger, D., Erickson, S.L., Yee, S., Phillips, G., Chari, R., Sliwkowski, M.X. (2001). Potent preclinical efficacy of Herceptin-DM1 against HER2-over-expressing breast tumors in vivo. Abstract #652, AACR-NCI-EORTC International Conference (Miami Beach, FL: American Association for Cancer Res), 132.
35. Sedlacek H.-H., Seemann G., Hoffmann D., Czech J., Lorenze P., Kolar C., Bosslet K. Antibodies as Carriers of Cytotoxicity. Vol. 43:1992;Munich, Germany, Karger.
36. Senter, P.D., Doronina, S., Cerveny, C., Chace, D., Francisco, J., Klussman, K., Mendelsohn, B., Meyer, D., Siegall, C.B., Thompson, J., et al. (2002). Cures and regressions of established tumors with monoclonal antibody auristatin conjugates. Abstract #2062, American Assoication for Cancer Res. (San Francisco, CA: American Association for Cancer Res.), 414.
37. Sgouros G., Ballangrud A.M., Jurcic J.G., McDevitt M.R., Humm J.L., Erdi Y.E., Mehta B.M., Finn R.D., Larson S.M., Scheinberg D.A. J. Nucleic Med. 40:1999;1935-1946.
38. Sievers E.L., Linenberger M. Curr. Opin. Oncol. 13:2001;522-527.
39. Sievers E.L., Larson R.A., Stadtmauer E.A., Estey E., Lowenberg B., Dombret H., Karanes C., Theobald M., Bennett J.M., Sherman M.L., et al. J. Clin. Oncol. 19:2001;3244-3254.
40. Tolcher A.W. J. Clin. Oncol. 18:2000;4000.
41. Tolcher A.W., Sugarman S., Gelmon K.A., Cohen R., Saleh M., Isaacs C., Young L., Healey D., Onetto N., Slichenmyer W. J. Clin. Oncol. 17:1999;478-484.
42. Tolcher A.W., Ochoa L., Hammond L.A., Patnaik A., Edwards T., Takimoto C., Smith L., de Bono J., Schwartz G., Mays T., et al. J. Clin. Oncol. 21:2003;211-222.